DealsJun 2, 2026, 08:11 AM
UroGen Pharma settles Jelmyto patent suit with Teva
AI Summary
UroGen Pharma Ltd. announced a settlement and license agreement with Teva Pharmaceuticals, Inc., resolving patent litigation related to Jelmyto® (mitomycin) for pyelocalyceal solution. Under the terms, UroGen will grant Teva a non-exclusive license to sell its generic version of Jelmyto, with sales commencing on September 15, 2030, if approved by the FDA. This agreement will lead to the termination of all ongoing patent litigation between the companies.
Key Highlights
- UroGen Pharma Ltd. settled patent litigation with Teva Pharmaceuticals, Inc. regarding Jelmyto® (mitomycin) for pyelocalyceal solution.
- The settlement includes a license agreement allowing Teva to sell a generic version of Jelmyto.
- Teva's generic version can be sold starting September 15, 2030, pending FDA approval.
- The agreement resolves patent litigation stemming from Teva's Abbreviated New Drug Application (ANDA).
- All ongoing patent litigation between the parties in the U.S. District Court for the District of Delaware will be terminated.
- The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Price Impact
More from URGN